Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +44 1494 818 026 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
+44 1494 818 026

I have recently had the pleasure of dealing with Zenopa's pharmaceutical recruitment team. I just wanted to let you know how supportive.
Agatha, 2013

Merck Sharpe and Dohme reports positive Zostavax trial data

3 April 2012 00:00 in Pharmaceutical Company Product News

Merck Sharpe and Dohme has announced positive phase III clinical trial data for Zostavax, its vaccine therapy for herpes zoster, also known as shingles.

Results from a study trialling the drug among adult patients aged between 50 and 59 has been published in the latest issue of the medical journal Clinical Infectious Diseases, highlighting its benefits compared to placebo.

Over the course of the study, patients receiving Merck's vaccine were shown to experience a significantly reduced risk of developing shingles compared to those in the control group, with rates falling by nearly 70 percent.

Data from this trial has already been used to support the drug's US approval for use among this patient group last year.

Dr Myron Levin, one of the study's investigators and professor of paediatrics and medicine at the University of Colorado Denver School of Medicine, said: "The results of this study demonstrate the importance of Zostavax to help prevent shingles in adults ages 50 to 59."

Last month, the company also reported positive phase III trial data for vorapaxar, an investigational antithrombotic medicine for the prevention of cardiovascular events.ADNFCR-8000103-ID-801332487-ADNFCR

Other news stories from 03/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency

© Copyright 2015 Zenopa Ltd